Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial,Leukemia

当前位置： X-MOL 学术 › Leukemia › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
Leukemia ( IF 11.4 ) Pub Date : 2022-06-25 , DOI: 10.1038/s41375-022-01629-7
Julia von Tresckow _{1,

2} , Paula Cramer ₁ , Sandra Robrecht ₁ , Petra Langerbeins ₁ , Anna-Maria Fink ₁ , Othman Al-Sawaf ₁ , Moritz Fürstenau ₁ , Thomas Illmer ₃ , Holger Klaproth ₄ , Eugen Tausch ₅ , Matthias Ritgen ₆ , Kirsten Fischer ₁ , Clemens-Martin Wendtner _{1,

7} , Karl-Anton Kreuzer ₁ , Stephan Stilgenbauer _{5,

8} , Sebastian Böttcher ₉ , Barbara F Eichhorst ₁ , Michael Hallek ₁₀

Affiliation

Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
BAG Freiberg-Richter, Jacobasch, Wolf, Illmer, Dresden, Germany.
Hämatologische/ Onkologische Praxis Dr. Klaproth, Neunkirchen, Germany.
Department of Internal Medicine III, Ulm University, Ulm, Germany.
Department of Medicine II, University of Schleswig-Holstein, Kiel, Germany.
Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Munich, Germany.
Department of Internal Medicine I, Saarland University, Homburg, Germany.
Clinic for Internal Medicine III (Hematology, Oncology, Palliative Care), Rostock University Medical School Rostock, Rostock, Germany.
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, CECAD Cluster of Excellence at the University of Cologne, Clinical Research Unit (KFO) 286, German CLL Study Group, University of Cologne, Cologne, Germany.